|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ticagrelor#Overdosage]] |
| {{Ticagrelor}}
| |
| {{CMG}}; {{AE}} {{JH}}
| |
| | |
| ==Overdosage==
| |
| | |
| There is currently no known treatment to reverse the effects of BRILINTA, and ticagrelor is not expected to be dialyzable. Treatment of overdose should follow local standard medical practice. Bleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken.
| |
| | |
| Other effects of overdose may include gastrointestinal effects ([[nausea]], [[vomiting]], [[diarrhea]]) or ventricular pauses. Monitor the [[ECG]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = BRILINTA (TICAGRELOR)TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 | publisher = |date = | accessdate = 26 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:ADP receptor inhibitors]]
| |
| [[Category:Triazolopyrimidines]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Alcohols]]
| |
| [[Category:AstraZeneca]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |